Epidermolysis Bullosa Gene Therapy Effort Gains FDA Guidance – Pharmaceutical Processing
Pharmaceutical Processing |
Epidermolysis Bullosa Gene Therapy Effort Gains FDA Guidance
Pharmaceutical Processing Abeona Therapeutics receives guidance from FDA to commence pivotal phase 3 for EB-101 gene therapy for patients with epidermolysis bullosa. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel gene … Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2% Maxim Group Just Issued “Buy” Rating on Abeona Therapeutics Inc (ABEO) Analysts are on the Bearish side about Abeona Therapeutics Inc (NASDAQ:ABEO) this week. |
